Focal Vitiligo: Symptoms, Progression, and Treatment Options

Focal vitiligo is one or a few small depigmented patches confined to a limited area of skin. There is no nerve-line pattern (that is segmental vitiligo), no widespread involvement across the body (that is generalised non-segmental vitiligo), just a small, localised loss of pigment that often shows up before anyone has worked out exactly what kind of vitiligo they are dealing with.

It is frequently the first presentation. Someone notices a pale spot on their face or hand, goes to a dermatologist, and gets told it is vitiligo — specifically focal vitiligo, for now. That “for now” is what most people want to understand. This article covers what focal vitiligo actually looks like, how likely it is to progress, how it behaves in children, and what treatment options exist.

What makes focal vitiligo different from other types

Vitiligo is broadly divided into non-segmental vitiligo (NSV) and segmental vitiligo (SV). Focal vitiligo sits within the NSV family but represents its earliest, most limited form. Understanding where it fits helps make sense of prognosis and treatment decisions.

Feature	Focal	Segmental	Generalised NSV
Distribution	One or a few patches in a limited area	One side of the body, following a dermatomal pattern	Bilateral, scattered across multiple body areas
Spread pattern	May stay focal or progress to generalised NSV	Rapid initial spread, then usually stable	Episodic flares, often triggered by stress or trauma
Autoimmune mechanism	Autoimmune, same as generalised NSV	Different mechanism - less autoimmune, more neurogenic	Classic autoimmune attack on melanocytes
Treatment response	Generally good for topicals and narrowband UVB	Responds to treatment but recurrence is common	Variable; best results on face, poor on hands and feet

The key distinction from segmental vitiligo is that focal patches do not follow nerve distribution lines. The key distinction from generalised NSV is that the patches are limited in number and location. It is possible for focal vitiligo to progress into generalised NSV over time — that is what most patients are worried about — but it is not inevitable.

Symptoms and appearance

Focal vitiligo appears as sharply defined patches with complete or near-complete loss of pigment. On fair skin the patches look milk-white. On darker skin they appear chalk-white or porcelain-white, making the contrast more pronounced.

The patches themselves are usually:

Small — often under two centimetres when first noticed
Located in proximity to each other if there are multiple patches (not scattered across the body)
Most common on the face, hands, and neck in first presentation
Smooth-bordered with clear demarcation from surrounding normal skin

Two things worth knowing about how they appear:

Koebner phenomenon — new patches can form at sites of physical trauma. Cuts, friction, sunburn, and even tight clothing can trigger depigmentation in someone with active vitiligo. This is not unique to focal vitiligo, but it explains why a single patch sometimes appears after an injury to that area.

Leucotrichia — when white hairs grow within a patch, it indicates the hair follicle melanocytes have been depleted. This matters because follicular melanocytes are the main reservoir from which repigmentation occurs. A patch with extensive leucotrichia responds more slowly to treatment, and repigmentation may be incomplete.

Does focal vitiligo spread?

This is the question almost everyone asks first. The honest answer is: it can, but it does not always, and some focal cases remain localised for years or permanently.

The clearest data comes from a long-term follow-up study of 52 focal vitiligo patients (Inamadar et al., 2016). Over a median follow-up of 7 years, 23% progressed to generalised non-segmental vitiligo. Progression was not evenly distributed: about half of those who progressed did so within the first 2 years; the other half progressed after the 2-year mark. Critically, none of the focal cases in this study progressed to segmental vitiligo. And no baseline clinical features reliably predicted who would progress — the researchers found no markers at diagnosis that separated those who stayed focal from those who spread. That means 77% of patients remained focal over a 7-year window.

The most predictive factor is behaviour in the first 12-18 months. Active spread during the first year - new patches appearing, existing patches enlarging at the edges - indicates a more aggressive disease course. Stability over 12-18 months is a relatively reassuring sign, though not a guarantee.

Other factors that increase spread risk:

Personal or family history of autoimmune disease (thyroid disease in particular)
Koebner responses - if trauma consistently triggers new patches, the skin is more reactive
Sun damage and burns to depigmented or surrounding skin
High psychological stress - not definitively proven as a trigger, but consistent in patient reports and plausible via immune mechanisms

What focal vitiligo does not mean: it does not mean widespread disease is coming. Starting with a focal pattern is not the same as having generalised NSV that has not spread yet. Many people live with one or two stable patches for decades. The trajectory matters more than the starting point.

Focal vitiligo in children

Up to 50% of paediatric vitiligo cases begin as a focal pattern. Children are not just small adults when it comes to vitiligo — their immune systems differ, their skin responds differently to treatment, and the psychological context is different.

For a small, stable focal patch in a child, watchful waiting is often appropriate. Not every small patch requires immediate aggressive treatment. Dermatologists typically monitor for 6-12 months before escalating beyond a gentle topical.

When to escalate treatment in children:

Rapid spread over weeks or months
Involvement of the face, especially around the eyes and mouth (high-visibility, emotionally significant)
Involvement of hands (can affect social interactions for a child)
Significant distress in the child or family

Treatment in children:

Tacrolimus 0.03% ointment — the standard off-label first-line choice for children, particularly for facial patches. Well-tolerated, no risk of skin atrophy unlike steroids. Applied twice daily.
Low-potency topical corticosteroids — short courses, typically 3-4 weeks on, with breaks to prevent atrophy. More commonly used on body than face.
Ruxolitinib cream (Opzelura) — FDA-approved for non-segmental vitiligo in patients aged 12 and over. Stronger evidence than tacrolimus but cost is a significant barrier without insurance coverage.
Narrowband UVB — usually reserved for multiple patches or when topicals have failed. For a single small focal patch, phototherapy is generally not the first step.

The emotional and social impact of vitiligo in school-age children should not be underestimated. A visible patch on the face can lead to questions, teasing, and self-consciousness during formative years. Early dermatology involvement, even for a small patch, means a child and their family get proper information — which reduces anxiety and helps them make informed decisions about whether and how to treat.

Treatment options

Treatment for focal vitiligo follows the same principles as for other forms of NSV. The advantage of focal vitiligo is that the surface area is small, which limits exposure to topical medications and makes treatment more manageable.

Topical calcineurin inhibitors (tacrolimus, pimecrolimus) First choice for most focal patches, especially on the face, neck, and around eyes — areas where corticosteroid use is restricted due to atrophy risk. Applied twice daily. Takes 3-6 months of consistent use to see meaningful repigmentation. Well-tolerated; burning or stinging in the first week or two usually settles.

Topical corticosteroids Effective for body patches away from the face. Used in short cycles (typically 4 weeks on, 2-4 weeks off) to reduce risk of skin thinning and telangiectasia. Medium-potency steroids are standard; stronger steroids reserved for resistant body patches.

Ruxolitinib cream (Opzelura) The strongest topical evidence for NSV repigmentation. FDA-approved for NSV in patients aged 12 and over. Studies show meaningful facial repigmentation in around 30% of patients at 24 weeks, with continued improvement to 52 weeks. Cost and insurance coverage are the practical barriers for most patients. See the ruxolitinib article for detail on evidence and cost.

Phototherapy (narrowband UVB) Typically reserved for cases where focal vitiligo has begun to spread, or where topicals have failed after 6 months. For a single small stable patch, the time commitment and equipment cost of phototherapy is generally not warranted as a first step. If spreading is documented, narrowband UVB is a reasonable next escalation.

Watchful waiting A legitimate option for a small, stable focal patch — particularly in children and in adults with a patch in a non-visible location who are not distressed by it. Monitoring every 3-6 months allows early detection of spread without committing to treatment that may not be necessary.

When to see a dermatologist

Not every focal patch requires urgent dermatology referral, but these situations warrant prompt attention:

New patches appearing elsewhere on the body
An existing patch growing at the edges over weeks
Patches on the face or hands (high-visibility and worth treating promptly)
A child is affected, at any age
Significant distress about appearance or progression
Uncertainty about whether it is vitiligo at all (other conditions can cause localised depigmentation)

A proper diagnosis matters even for a small patch. Conditions like pityriasis alba, post-inflammatory hypopigmentation, and tinea versicolor can look similar to early focal vitiligo and have different treatments. Getting the diagnosis confirmed means any treatment decisions are grounded in what is actually happening in the skin.

Beth’s take

Focal vitiligo is, genuinely, the better news within the vitiligo spectrum. A single stable patch two years after it first appeared has a very different outlook from spreading patches arriving monthly. The anxiety about “will it spread?” is completely understandable - it is a reasonable question, not an irrational fear. But the answer is “maybe, and here is what to watch for” rather than a yes. Watch the first 12-18 months closely, protect the skin from Koebner triggers, and treat if there is spread or significant distress. Stability is your best prognostic sign.

Related reading: